度普利尤单抗相关头颈部皮炎研究进展

doi:10.35541/cjd.20250040

中华皮肤科杂志 ›› 2026, e20250040.doi: 10.35541/cjd.20250040

度普利尤单抗相关头颈部皮炎研究进展

李子帆¹ 余若熙¹ 林颖²

1广州中医药大学第二临床医学院，广州 510006 ；2广东省中医院皮肤科广东省中医皮肤临床医学研究中心广东省中医药防治难治性慢病重点实验室，广州 510120

收稿日期:2025-01-23 修回日期:2026-06-12 发布日期:2026-08-10
通讯作者: 林颖 E-mail:lin19791226@gzucm.edu.cn
基金资助:
广州市科技计划项目（2025A03J1129）；广东省中医院中医药科学技术专项（YN2023MS23）

Dupilumab?associated head and neck dermatitis

Li Zifan¹, Yu Ruoxi¹, Lin Ying²

¹The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; ²Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Clinical Research Center for Chinese Medicine Dermatology, Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 510120, China

Received:2025-01-23 Revised:2026-06-12 Published:2026-08-10
Contact: Lin Ying E-mail:lin19791226@gzucm.edu.cn
Supported by:
The Science and Technology Planning Project of Guangzhou （2025A03J1129）; Chinese Medicine Science and Technology Research Project of Guangdong Provincial Hospital of Chinese Medicine （YN2023MS23）

摘要/Abstract

摘要： 【摘要】度普利尤单抗治疗特应性皮炎疗效显著，但同时也伴随一种值得关注的不良反应——度普利尤单抗相关头颈部皮炎（DAHND）。本文系统总结了DAHND的发病情况、发病机制及诊疗策略，为临床医生识别和管理度普利尤单抗相关不良反应提供参考。

关键词: 皮炎, 特应性, 面部皮肤病, 抗体, 单克隆, 药物相关性不良反应, 诊断, 治疗

Abstract: 【Abstract】 Dupilumab has demonstrated remarkable efficacy in the treatment of atopic dermatitis; however, it is also associated with a noteworthy adverse reaction—dupilumab?associated head and neck dermatitis （DAHND）. This review systematically summarizes the epidemiology, pathogenesis, and diagnostic and therapeutic strategies for DAHND, with the aim of providing clinicians with a reference for identifying and managing adverse reactions related to dupilumab.

Key words: Dermatitis, atopic, Facial dermatoses, Antibodies, monoclonal, Drug?related side effects and adverse reactions, Diagnosis, Therapy

李子帆余若熙林颖. 度普利尤单抗相关头颈部皮炎研究进展[J]. 中华皮肤科杂志, 2026,e20250040. doi:10.35541/cjd.20250040

Li Zifan¹, Yu Ruoxi¹, Lin Ying². Dupilumab?associated head and neck dermatitis[J]. Chinese Journal of Dermatology,2026,e20250040. doi:10.35541/cjd.20250040

参考文献 52

［1］	Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs［J］. Nat Rev Drug Discov, 2023,22（9）:743⁃767. DOI: 10.1038/s41573⁃023⁃00750⁃1.
［2］	中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（2）:97⁃108. DOI: 10.35541/cjd.20230358.
［3］	马东霞, 祝戎飞, 邹晓燕. 度普利尤单抗引起儿童面部红斑1例［J］. 中国皮肤性病学杂志, 2025,39（2）:202⁃206. DOI: 10. 13735/j.cjdv.1001⁃7089.202405042.
［4］	D'Agostino M, Potestio L, Patruno C, et al. The use of dupilumab in difficult⁃to⁃treat areas of atopic dermatitis: lessons from real⁃world studies［J］. Clin Exp Dermatol, 2026,51（2）:202⁃211. DOI: 10.1093/ced/llaf441.
［5］	Ahn J, Lee DH, Na CH, et al. Facial erythema in patients with atopic dermatitis treated with dupilumab ⁃ a descriptive study of morphology and aetiology［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2140⁃2152. DOI: 10.1111/jdv.18327.
［6］	中华医学会皮肤性病学分会特应性皮炎研究中心，中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识［J］. 中华皮肤科杂志，2022，55（6）：465⁃470. DOI：10.35541/cjd.20210885.
［7］	Kozera E, Stewart T, Gill K, et al. Dupilumab⁃associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia⁃specific IgE: a multicentre, prospective cohort study［J］. Br J Dermatol, 2022,186（6）:1050⁃1052. DOI: 10. 1111/bjd.21019.
［8］	Ashbaugh AG, Murase EM, Raffi J, et al. Characterization of residual facial dermatitis during dupilumab therapy: a retrospective chart review to delineate the potential role of expanded series patch testing［J］. Dermatitis, 2022,33（1）:51⁃61. DOI: 10.1097/DER.0000000000000801.
［9］	Soria A, Du⁃Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab［J］. JAMA Dermatol, 2019,155（11）:1312⁃1315. DOI: 10.1001/jamadermatol.2019. 2613.
［10］	Napolitano M, Fabbrocini G, Patruno C. Dupilumab⁃associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study［J］. J Dermatol, 2023,50（7）:880⁃887. DOI: 10.1111/1346⁃8138.16764.
［11］	Dybała A, Sernicola A, Gomes V, et al. Dupilumab facial redness: histologic characterization on a series of four cases［J］. Immunotherapy, 2022,14（4）:183⁃188. DOI: 10.2217/imt⁃2021⁃0122.
［12］	Gu C, Wu Y, Luo Y, et al. Real⁃world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single⁃centre, prospective, open⁃label study［J］. J Eur Acad Dermatol Venereol, 2022,36（7）:1064⁃1073. DOI: 10.1111/jdv.18109.
［13］	Muzumdar S, Zubkov M, Waldman R, et al. Characterizing dupilumab facial redness in children and adolescents: a single⁃institution retrospective chart review［J］. J Am Acad Dermatol, 2020,83（5）:1520⁃1521. DOI: 10.1016/j.jaad.2020.06.1003.
［14］	Ferrucci S, Angileri L, Tavecchio S, et al. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease［J］. J Dermatolog Treat, 2022,33（5）:2587⁃2592. DOI: 10.1080/09546634.2022.2049588.
［15］	de Beer FSA, Bakker DS, Haeck I, et al. Dupilumab facial redness: positive effect of itraconazole［J］. JAAD Case Rep, 2019, 5（10）: 888⁃891. DOI: 10.1016/j.jdcr.2019.07.020.
［16］	Russo F, Rizzo A, Santi F, et al. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis［J］. Int J Dermatol, 2022, 61（6）: e204⁃e206. DOI: 10.1111/ijd.15871.
［17］	Quint T, Brunner PM, Sinz C, et al. Dupilumab for the treatment of atopic dermatitis in an Austrian cohort⁃real⁃life data shows rosacea⁃like folliculitis［J］. J Clin Med, 2020,9(4):1241. DOI: 10.3390/jcm9041241.
［18］	Chong AC, Navarro ⁃ Triviño FJ, Su M, et al. Fungal head and
	neck dermatitis: current understanding and management［J］.
	Clin Rev Allergy Immunol, 2024,66（3）:363⁃375. DOI: 10.1007/
	s12016⁃024⁃09000⁃7.
［19］	See Tow HX, Yew YW. Malassezia specific IgE in head and neck dermatitis of eczema: a systematic review & meta⁃analysis［J］. Exp Dermatol, 2024,33（6）:e15108. DOI: 10.1111/exd.15108.
［20］	Umemoto N, Kakurai M, Matsumoto T, et al. Dupilumab alters both the bacterial and fungal skin microbiomes of patients with atopic dermatitis［J］. Microorganisms, 2024,12（1）:224. DOI: 10.3390/microorganisms12010224.
［21］	Kozera E, Flora A, Stewart T, et al. Dupilumab⁃associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia⁃specific immunoglobulin E levels mirroring clinical response［J］. J Am Acad Dermatol, 2023,88（1）:255⁃257. DOI: 10.1016/j.jaad.2022.05.021.
［22］	Yamamura Y, Nakashima C, Otsuka A. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from murin models and human［J］. Front Med （Lausanne）, 2024,11:1342176. DOI: 10.3389/fmed.2024.1342176.
［23］	Laska J, Tota M, Łacwik J, et al. IL⁃22 in atopic dermatitis［J］. Cells, 2024,13（16）:1398. DOI: 10.3390/cells13161398.
［24］	Nograles KE, Zaba LC, Guttman⁃Yassky E, et al. Th17 cytokines interleukin （IL）⁃17 and IL⁃22 modulate distinct inflammatory and keratinocyte⁃response pathways［J］. Br J Dermatol, 2008,159（5）:1092⁃1102. DOI: 10.1111/j.1365⁃2133.2008.08769.x.
［25］	Sparber F, De Gregorio C, Steckholzer S, et al. The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti⁃fungal immunity and exacerbates skin inflammation［J］. Cell Host Microbe, 2019,25（3）:389⁃403. DOI: 10.1016/j.chom.2019.02.002.
［26］	Bangert C, Alkon N, Chennareddy S, et al. Dupilumab⁃associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells［J］. Nat Commun, 2024,15（1）:2839. DOI: 10.1038/s41467⁃024⁃46540⁃0.
［27］	Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: a report of two cases［J］. J Eur Acad Dermatol Venereol, 2023,37（3）:e300⁃e302. DOI: 10.1111/jdv.18743.
［28］	El⁃Moamly A, El⁃Swify O. Raising awareness of Demodex mites: a neglected cause of skin disease［J］. Infection, 2025,53（4）:1273⁃1298. DOI: 10.1007/s15010⁃025⁃02521⁃z.
［29］	Wei F, Li L, Kong Y, et al. Evidence for the clinical association between Demodex and rosacea: a review［J］. Dermatology, 2024,240（1）:95⁃102. DOI: 10.1159/000534245.
［30］	Wang H, Zhou C. Advances in the pathogenesis of rosacea［J］. Front Immunol, 2025,16:1705588. DOI: 10.3389/fimmu.2025. 1705588.
［31］	Ricardo⁃Gonzalez RR, Kotas ME, O'Leary CE, et al. Innate type 2 immunity controls hair follicle commensalism by Demodex mites［J］. Immunity, 2022,55（10）:1891⁃1908. DOI: 10.1016/j.immuni.2022.08.001.
［32］	Gazi U, Gureser AS, Oztekin A, et al. Skin⁃homing T⁃cell responses associated with Demodex infestation and rosacea［J］. Parasite Immunol, 2019, 41（8）: e12658. DOI: 10.1111/pim.12658.
［33］	Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen⁃dependent differences in immune response［J］. J Allergy Clin Immunol, 2014,134（2）:362⁃372. DOI: 10.1016/j.jaci.2014.03.009.
［34］	Bocquel S, Soria A, Raison⁃Peyron N, et al. Impact of dupilumab on patch test results and allergic contact dermatitis: a prospective multicenter study［J］. J Am Acad Dermatol, 2024,90（3）:512⁃520. DOI: 10.1016/j.jaad.2023.10.029.
［35］	Mufti A, Lu JD, Sachdeva M, et al. Patch testing during immunosuppressive therapy: a systematic review［J］. Dermatitis, 2021,32（6）:365⁃374. DOI: 10.1097/DER.0000000000000726.
［36］	Chu D, Tao K, Guo W, et al. Effect of dupilumab therapy on patch test results for atopic contact dermatitis: a systematic review［J］. Int J Dermatol, 2026,65（4）:819⁃821. DOI: 10.1111/ijd.70041.
［37］	Takeshita K, Yamasaki T, Akira S, et al. Essential role of MHC Ⅱ⁃independent CD4+ T cells, IL⁃4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse［J］. Int Immunol, 2004, 16（5）: 685⁃695. DOI: 10.1093/intimm/dxh073.
［38］	Crepy MN, Nosbaum A, Bensefa⁃Colas L. Blocking type 2 inflammation by dupilumab does not control classic （type 1⁃driven） allergic contact dermatitis in chronic hand eczema［J］. Contact Dermatitis, 2019,81（2）:145⁃147. DOI: 10.1111/cod. 13266.
［39］	Trimeche K, Lahouel I, Belhadjali H, et al. Contact allergy in atopic dermatitis: a prospective study on prevalence, incriminated allergens and clinical insights［J］. Contact Dermatitis, 2024, 90（5）: 514⁃519. DOI: 10.1111/cod.14494.
［40］	Su Z, Zeng YP. Dupilumab⁃associated psoriasis and psoriasiform manifestations: a scoping review［J］. Dermatology, 2023,239（4）:646⁃657. DOI: 10.1159/000530608.
［41］	Li Y, Liu H, Zhang F. Biologics⁃induced immunophenotypic cross⁃switching in patients with psoriasis and atopic dermatitis［J］. Indian J Dermatol, 2023,68（2）:186⁃191. DOI: 10.4103/ijd.ijd_871_22.
［42］	Burlando M, Schiavetti I, Parodi A, et al. Biologic treatments for psoriasis have different anatomical specificities in residual PASI［J］. J Dtsch Dermatol Ges, 2026, 24（5）: 628⁃632. DOI: 10.1111/ddg.15924.
［43］	Waldman RA, DeWane ME, Sloan B, et al. Characterizing dupilumab facial redness: a multi⁃institution retrospective medical record review［J］. J Am Acad Dermatol, 2020,82（1）:230⁃232. DOI: 10.1016/j.jaad.2019.06.026.
［44］	Seok SH, An JH, Shin JU, et al. Facial redness in atopic dermatitis patients treated with dupilumab: a case series［J］. Allergy Asthma Immunol Res, 2020,12（6）:1063⁃1065. DOI: 10.4168/aair.2020.12.6.1063.
［45］	Choi H, Shim DH, Kim MS, et al. New onset of alcohol flushing in an atopic dermatitis patient treated with dupilumab［J］. Ann Dermatol, 2023,35（Suppl 1）:S163⁃S164. DOI: 10.5021/ad. 21b.038.
［46］	Tsai YC, Tsai TF. Facial erythema during dupilumab treatment for atopic dermatitis successfully remedied with topical crisaborole ointment: a case report［J］. Dermatol Ther, 2022, 35（11）: e15843. DOI: 10.1111/dth.15843.
［47］	Gao DX, Song S, Kahn JS, et al. Treatment of patients experiencing dupilumab facial redness with itraconazole and fluconazole: a single⁃institutional, retrospective medical record review［J］. J Am Acad Dermatol, 2022,86（4）:938⁃940. DOI: 10.1016/j.jaad.2021.03.070.
［48］	Liane JG, Morgado⁃Carrasco D. Dupilumab⁃associated facial erythema successfully treated with oral ivermectin［J］. Dermatol Pract Concept, 2022,12（4）:e2022184. DOI: 10.5826/dpc.1204 a184.
［49］	艾丽珍, 余兰慧, 赖瑶, 等. 不同浓度茶树精油治疗蠕形螨睑缘炎的有效性及安全性［J］. 国际眼科杂志, 2022,22（1）:104⁃108. DOI: 10.3980/j.issn.1672⁃5123.2022.1.22.
［50］	Beyrouti A, Deuze J, Fontas E, et al. Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study［J］. J Allergy Clin Immunol Pract, 2025,13（2）:353⁃360. DOI: 10.1016/j.jaip.2024.12.001.
［51］	Santosa A, Yew YW. Dupilumab⁃associated head and neck dermatitis: rapid response with abrocitinib treatment［J］. Skin Health Dis, 2024,4（1）:e312. DOI: 10.1002/ski2.312.
［52］	Takegami T, Yonekura S, Kataoka K, et al. A case of dupilumab⁃resistant facial erythema successfully managed with topical delgocitinib［J］. J Dermatol, 2025,52（7）:e592⁃e593. DOI: 10.1111/1346⁃8138.17713.

[1]	梁云生. [开放获取] 慢性手部湿疹评估现状及进展[J]. 中华皮肤科杂志, 2026, 59(9): 850-855.
[2]	尹昊媛陆嘉怡王来陆前进. 香叶基香叶基转移酶Ⅱ调控特应性皮炎B细胞功能的作用及机制研究[J]. 中华皮肤科杂志, 2026, 59(9): 856-865.
[3]	陈圣安, 王兰庭, 陈虎艳杨凡萍, 骆肖群, . 嗜酸性肉芽肿性多血管炎的皮肤及系统受累特征与治疗转归：16例病例分析[J]. 中华皮肤科杂志, 2026, 59(9): 866-872.
[4]	唐祯刘宇航杨凌胡凌雪贺治杰曹凯丁澍. 反射式共聚焦显微镜在皮肤型红斑狼疮诊断与鉴别诊断中的价值及特征分析[J]. 中华皮肤科杂志, 2026, 59(9): 873-880.
[5]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2026, 59(9): 905-910.
[6]	《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（版）》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 728-737.
[7]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国皮肤鳞状细胞癌诊疗指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 703-716.
[8]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. [开放获取] 脓疱型银屑病诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 717-727.
[9]	李燕红姜琨吴卓璇章建兰方美珍刘姝婷王琳琳胡磊周小勇陈柳青陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787.
[10]	何庆张涛王秀丽高兴华陈洪铎柳敏齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(7): 687-690.
[11]	魏瑾闫会文张建中伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674.
[12]	王琳琳曹立娟陈柳青李东升胡燕燕. 海姆泊芬光动力疗法治疗四肢鲜红斑痣疗效观察及安全性回顾分析[J]. 中华皮肤科杂志, 2026, 59(7): 637-644.
[13]	刘怿菲金炫沃刘鹏月张希萌吴严. 点阵CO2激光联合A型肉毒毒素外用治疗面部毛孔粗大的半脸自身对照临床试验[J]. 中华皮肤科杂志, 2026, 59(7): 645-653.
[14]	张国龙赵子君. 氨基酮戊酸光动力疗法治疗皮肤鳞状细胞癌的现状、挑战和思考[J]. 中华皮肤科杂志, 2026, 59(7): 626-631.
[15]	中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 595-610.

度普利尤单抗相关头颈部皮炎研究进展

Dupilumab?associated head and neck dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 52

相关文章 15

Metrics

本文评价

推荐阅读 10